MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 576208 | Name: HC-1119
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deutenzalutamide-d3, also known as HC-1119 and MDV3100-d3, Enzalutamide D3; is an anti-androgen and antineoplastic. HC-1119 is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.

Chemical Structure

HC-1119
HC-1119
CAS#1443331-82-5

Theoretical Analysis

MedKoo Cat#: 576208

Name: HC-1119

CAS#: 1443331-82-5

Chemical Formula: C21H13D3F4N4O2S

Exact Mass: 467.1118

Molecular Weight: 467.46

Elemental Analysis: C, 53.96; H, 4.10; F, 16.26; N, 11.99; O, 6.85; S, 6.86

Price and Availability

Size Price Availability Quantity
1mg USD 450.00 2 Weeks
5mg USD 750.00 2 Weeks
10mg USD 1,350.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Deutenzalutamide; Enzalutamide D3; HC-1119; HC 1119; HC1119; Deutenzalutamide-d3; MDV3100-d3; MDV-3100-d3; MDV 3100-d3;
IUPAC/Chemical Name
Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)-
InChi Key
WXCXUHSOUPDCQV-HPRDVNIFSA-N
InChi Code
InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)/i3D3
SMILES Code
[2H]C([2H])([2H])NC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 467.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Shin WS, Han SH, Jo KW, Cho Y, Kim KT. Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer. Sci Rep. 2023 Oct 4;13(1):16663. doi: 10.1038/s41598-023-43561-5. PMID: 37794090. 2: Khan MA, Singh D, Jameel M, Maurya SK, Singh S, Akhtar K, Siddique HR. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy. Toxicol Appl Pharmacol. 2023 Sep 28;478:116699. doi: 10.1016/j.taap.2023.116699. Epub ahead of print. PMID: 37777120. 3: Giraud EL, Te Brake LMH, van den Hombergh ECA, Desar IME, Kweekel DM, van Erp NP. Results of the first international quality control programme for oral targeted oncolytics. Br J Clin Pharmacol. 2023 Sep 30. doi: 10.1111/bcp.15918. Epub ahead of print. PMID: 37776845. 4: Goktas Aydin S, Kutlu Y, Muglu H, Aydin A, Acikgoz O, Hamdard J, Karci E, Bilici A, Olmez OF, Yildiz O. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Cancer Chemother Pharmacol. 2023 Sep 29. doi: 10.1007/s00280-023-04592-x. Epub ahead of print. PMID: 37773537. 5: Nagata Y, Jojima K, Matsukawa T, Tomisaki I, Fujimoto N. Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer. Anticancer Res. 2023 Oct;43(10):4573-4581. doi: 10.21873/anticanres.16651. PMID: 37772559. 6: Shagera QA, Karfis I, Kristanto P, Spyridon S, Diamand R, Santapau A, Peltier A, Roumeguère T, Flamen P, Artigas C. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors. J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874. Epub ahead of print. PMID: 37770114. 7: Thankan RS, Thomas E, Purushottamachar P, Weber DJ, Ramamurthy VP, Huang W, Kane MA, Njar VCO. VNLG-152R and its deuterated analogs potently inhibit/repress triple/quadruple negative breast cancer of diverse racial origins in vitro and in vivo by upregulating E3 Ligase Synoviolin 1 (SYVN1) and inducing proteasomal degradation of MNK1/2. Front Oncol. 2023 Sep 11;13:1240996. doi: 10.3389/fonc.2023.1240996. PMID: 37766871; PMCID: PMC10520556. 8: Karim S, Lowther J, Gyulay G, O'Sullivan D, Wallis CJD, Yip SM, Brenner DR, Boyne DJ, Cheung WY. A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS). Curr Oncol. 2023 Sep 1;30(9):8149-8158. doi: 10.3390/curroncol30090591. PMID: 37754506; PMCID: PMC10528640. 9: Sciarra A, Santarelli V, Santodirocco L, Frisenda M, Salciccia S, Casale P, Forte F, Mariotti G, Moriconi M, Cattarino S, Sciarra B, Bevilacqua G, Gentilucci A. Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients? Curr Oncol. 2023 Aug 30;30(9):8054-8067. doi: 10.3390/curroncol30090584. PMID: 37754499; PMCID: PMC10528501. 10: Lee YS, Kim SH, Tae JH, Chang IH, Kim TH, Myung SC, Kim M, Nguyen TT, Choi J, Kim JH, Kim JW, Choi SY. Oral chemotherapeutic agents in metastatic hormone- sensitive prostate cancer: A network meta-analysis of randomized controlled trials. Prostate Int. 2023 Sep;11(3):159-166. doi: 10.1016/j.prnil.2023.06.003. Epub 2023 Jul 4. PMID: 37745904; PMCID: PMC10513908. 11: Gan X, Liu Y, Wang X. Targeting androgen receptor in glioblastoma. Crit Rev Oncol Hematol. 2023 Sep 24;191:104142. doi: 10.1016/j.critrevonc.2023.104142. Epub ahead of print. PMID: 37742885. 12: Tang D, He J, Dai Y, Geng X, Leng Q, Jiang H, Sun R, Xu S. Retraction Note: Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer. Cancer Gene Ther. 2023 Sep 21. doi: 10.1038/s41417-023-00669-0. Epub ahead of print. PMID: 37735565. 13: Storås AH, Tsuruda K, Fosså SD, Andreassen BK. Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study. Acta Oncol. 2023 Sep 19:1-7. doi: 10.1080/0284186X.2023.2257876. Epub ahead of print. PMID: 37725527. 14: Du Z, Chen X, Zhu P, Lv Q, Yong J, Gu J. Knocking down SOX2 overcomes the resistance of prostate cancer to castration via notch signaling. Mol Biol Rep. 2023 Sep 16. doi: 10.1007/s11033-023-08757-y. Epub ahead of print. PMID: 37716921. 15: Tsujino T, Tokushige S, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Ohno T, Nakamori K, Maenosono R, Nishimura K, Yamazaki S, Uchimoto T, Yanagisawa T, Mori K, Urabe F, Tsuzuki S, Iwatani K, Yamamoto S, Takahara K, Inamoto T, Kimura T, Ohno Y, Shiroki R, Azuma H. Real- world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer. Cancer Med. 2023 Sep 14. doi: 10.1002/cam4.6536. Epub ahead of print. PMID: 37706578. 16: Hasterok S, Scott TG, Roller DG, Spencer A, Dutta AB, Sathyan KM, Frigo DE, Guertin MJ, Gioeli D. The androgen receptor does not directly regulate the transcription of DNA damage response genes. Mol Cancer Res. 2023 Sep 12. doi: 10.1158/1541-7786.MCR-23-0358. Epub ahead of print. PMID: 37698543. 17: Vaishampayan U. Global efficacy and clinical application of androgen receptor inhibitors in metastatic prostate cancer. Chin Clin Oncol. 2023 Sep 6:cco-23-59. doi: 10.21037/cco-23-59. Epub ahead of print. PMID: 37691348. 18: Slootbeek PHJ, Overbeek JK, Ligtenberg MJL, van Erp NP, Mehra N. PARPing up the right tree; an overview of PARP inhibitors for metastatic castration- resistant prostate cancer. Cancer Lett. 2023 Sep 7:216367. doi: 10.1016/j.canlet.2023.216367. Epub ahead of print. PMID: 37689306. 19: Choi HY, Chang JE. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. Int J Mol Sci. 2023 Sep 3;24(17):13618. doi: 10.3390/ijms241713618. PMID: 37686423; PMCID: PMC10487969. 20: Rahnea-Nita RA, Rebegea LF, Nechifor A, Mareș C, Toma RV, Stoian AR, Ciuhu AN, Andronache LF, Constantin GB, Rahnea-Nita G. The Complexity of Treatments and the Multidisciplinary Team-A Rare Case of Long-Term Progression-Free Survival in Prostate Cancer until Development of Liver and Brain Metastases. J Clin Med. 2023 Aug 27;12(17):5579. doi: 10.3390/jcm12175579. PMID: 37685646; PMCID: PMC10488423.

View History

GW-876167

GW-876167

RWJ-54428

RWJ-54428

zectivimodum

zectivimodum

Zeltociclib

Zeltociclib